Orphazyme surges after key drug candidate trial results

Strategic Partners A/S

23/08/2021 10:53

** Orphazyme  ORPHA.CO  jumps more than 20% after the Danish
biotech company posted results from the trial of its key drug
candidate for a genetic disorder Niemann-Pick disease type C,
two months after it was rejected in the U.S.
    ** Orphazyme said the Phase 2/3 trial for drug arimoclomol
showed a "statistically significant and clinically meaningful"
treatment effect  urn:newsml:reuters.com:*:nASN001KS2
    ** The company expects the drug to receive an opinion from
the Comitte for Medicinal Products for Human Use in Europe in
the fourth quarter
    ** Oprhazyme shares took a hit in June afte the U.S. Food
and Drug Administration (FDA) rejected arimoclomol  urn:newsml:reuters.com:*:nL2N2O00CG
    ** The company said it continues to evaluate the path
forward in the U.S. following the FDA response
    ** The shares were subject to a frenzied trading before the
FDA decision, becoming one of the so called "meme stocks"
 urn:newsml:reuters.com:*:nL5N2NW4IH
    

 (Reporting by Boleslaw Lasocki)
 ((boleslaw.lasocki@tr.com))